文献速递皮肤肿瘤

黑色素瘤免疫与靶向治疗时代的医疗费用、生存与时间毒性变化

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
PubMed 文献 · JAMA Dermatol · 2023-01-01

该回顾性队列研究基于加拿大安大略省居民数据,采用倾向评分匹配比较2018-2019年与2007-2012年诊断的II-IV期皮肤黑色素瘤患者。结果显示2018-2019年队列医疗费用和系统治疗费用更高,3年总生存率更高(74.2% vs 65.8%),时间毒性相似;IV期患者2018-2019年与医疗系统接触天数更多但差异无统计学意义。

要点

  • 2018-2019年队列医疗费用高于2007-2012年队列,III期和IV期差异明显。
  • 2018-2019年队列系统治疗费用在II、III、IV期均高于2007-2012年队列。
  • 2018-2019年队列3年OS高于2007-2012年队列(74.2% vs 65.8%)。

核心结论

  • 该队列研究发现II至IV期黑色素瘤治疗中医疗费用更高,IV期患者存在大量时间毒性,同时免疫治疗和靶向治疗的采用与OS改善相关。
  • 这些数据强调采用新疗法的权衡:医疗系统经济负担和患者时间负担增加,但生存相关改善。

研究设计与样本

  • 回顾性队列研究,采用倾向评分匹配,纳入加拿大安大略省20岁及以上II至IV期皮肤黑色素瘤居民。
  • 2018年1月1日至2019年3月31日队列与2007年1月1日至2012年12月31日历史比较队列匹配。
  • 匹配后每组731例,2018-2019组平均年龄67.9岁(SD 14.8),男性437例(59.8%);2007-2012组平均年龄67.9岁(SD 14.4),男性440例(60.2%)。

主要发现

  • 3年OS 2018-2019组为74.2%(95%CI 70.8%-77.2%),2007-2012组为65.8%(95%CI 62.2%-69.1%),HR 0.72(95%CI 0.61-0.85),P < .001。
  • 时间毒性两时代相似;IV期患者2018-2019组与医疗系统有身体接触的天数为58.7天(SD 43.8),2007-2012组为44.2天(SD 26.5),标准化差异0.40,P = .20。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on health care costs and outcomes in routine practice. OBJECTIVE: To examine changes in health care costs, overall survival (OS), and time toxicity associated with primary treatment of melanoma. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed a longitudinal, propensity score (PS)-matched, retrospective cohort of residents of Ontario, Canada, aged 20 years or older with stages II to IV cutaneous melanoma identified from the Ontario Cancer Registry from January 1, 2018, to March 31, 2019. A historical comparison cohort was identified from a population-based sample of invasive melanoma cases diagnosed from the Ontario Cancer Registry from January 1, 2007, to December 31, 2012. Data analysis was performed from October 17, 2022, to March 13, 2023. EXPOSURES: Era of melanoma diagnosis (2007-2012 vs 2018-2019). MAIN OUTCOMES AND MEASURES: The primary outcomes were mean per-capita health care and systemic therapy costs (Canadian dollars) during the first year after melanoma diagnosis, time toxicity (days with physical health care contact) within 1 year of initial treatment, and OS. Standardized differences were used to compare costs and time toxicity. Kaplan-Meier methods and Cox proportional hazards regression were used to compare OS among PS-matched cohorts. RESULTS: A PS-matched cohort of 731 patients (mean [SD] age, 67.9 [14.8] years; 437 [59.8%] male) with melanoma from 2018 to 2019 and 731 patients (mean [SD] age, 67.9 [14.4] years; 440 [60.2%] male) from 2007 to 2012 were evaluated. The 2018 to 2019 patients had greater mean (SD) health care (including systemic therapy) costs compared with the 2007 to 2012 patients ($47 886 [$55 176] vs $33 347 [$31 576]), specifically for stage III ($67 108 [$57 226] vs $46 511 [$30 622]) and stage IV disease ($117 450 [$79 272] vs $47 739 [$37 652]). Mean (SD) systemic therapy costs were greater among 2018 to 2019 patients: stage II ($40 823 [$40 621] vs $10 309 [$12 176]), III ($55 699 [$41 181] vs $9764 [$12 771]), and IV disease ($79 358 [$50 442] vs $9318 [$14 986]). Overall survival was greater for the 2018 to 2019 cohort compared with the 2007 to 2012 cohort (3-year OS: 74.2% [95% CI, 70.8%-77.2%] vs 65.8% [95% CI, 62.2%-69.1%], hazard ratio, 0.72 [95% CI, 0.61-0.85]; P < .001). Time toxicity was similar between eras. Patients with stage IV disease spent more than 1 day per week (>52 days) with physical contact with the health care system by 2018 to 2019 (mean [SD], 58.7 [43.8] vs 44.2 [26.5] days; standardized difference, 0.40; P = .20). CONCLUSIONS AND RELEVANCE: This cohort study found greater health care costs in the treatment of stages II to IV melanoma and substantial time toxicity for patients with stage IV disease, with improvements in OS associated with the adoption of immunotherapy and targeted therapies. These health system-wide data highlight the trade-off with adoption of new therapies, for which there is a greater economic burden to the health care system and time burden to patients but an associated improvement in survival.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Bateni SB, Nguyen P, Eskander A, et al. Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma. JAMA Dermatol. 2023. PMID: 37672282. doi:10.1001/jamadermatol.2023.3179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。